CA2929286A1 - Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique - Google Patents

Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique Download PDF

Info

Publication number
CA2929286A1
CA2929286A1 CA2929286A CA2929286A CA2929286A1 CA 2929286 A1 CA2929286 A1 CA 2929286A1 CA 2929286 A CA2929286 A CA 2929286A CA 2929286 A CA2929286 A CA 2929286A CA 2929286 A1 CA2929286 A1 CA 2929286A1
Authority
CA
Canada
Prior art keywords
mepe
mice
syndrome
treated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2929286A
Other languages
English (en)
Inventor
Lawrence Irwin Glass
Michael John Bickerdike
Michael Frederick Snape
Patricia Perez DE COGRAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd New Zealand
Original Assignee
Neuren Pharmaceuticals Ltd New Zealand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd New Zealand filed Critical Neuren Pharmaceuticals Ltd New Zealand
Publication of CA2929286A1 publication Critical patent/CA2929286A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2929286A 2012-11-28 2013-11-26 Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique Abandoned CA2929286A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730829P 2012-11-28 2012-11-28
US61/730,829 2012-11-28
PCT/US2013/072049 WO2014085480A1 (fr) 2012-11-28 2013-11-26 Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique

Publications (1)

Publication Number Publication Date
CA2929286A1 true CA2929286A1 (fr) 2014-06-05

Family

ID=50828422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929286A Abandoned CA2929286A1 (fr) 2012-11-28 2013-11-26 Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique

Country Status (6)

Country Link
EP (1) EP2928300A4 (fr)
JP (1) JP2016506380A (fr)
AU (1) AU2013352294A1 (fr)
BR (1) BR112015012506A2 (fr)
CA (1) CA2929286A1 (fr)
WO (1) WO2014085480A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180184964A1 (en) * 2014-06-30 2018-07-05 Cerora, Inc. System and signatures for a multi-modal physiological periodic biomarker assessment
PL3833358T3 (pl) * 2018-08-10 2024-03-04 New York University Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmu
MX2021001596A (es) 2018-08-10 2021-06-08 Univ New York Uso de manosa-6-fosfato y sus modificaciones para mejorar la memoria y reducir el daño mental.
WO2025169163A1 (fr) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Procédé de synthèse de trofinétide et de ses analogues

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127702A2 (fr) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogues de glycyl-prolyl-glutamate
ATE435852T1 (de) * 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US8637567B2 (en) * 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US8461148B2 (en) * 2004-09-20 2013-06-11 Icahn School Of Medicine At Mount Sinai Use of memantine (namenda) to treat autism, compulsivity and impulsivity
WO2007106555A2 (fr) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Préparations orales de glycyl-2-méthylpropyl-glutamate
PL2083811T3 (pl) * 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
WO2011146109A2 (fr) * 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Procédés et tests pour le traitement de sujets présentant une délétion, une mutation ou une expression réduite de shank3
SI2667715T1 (sl) * 2011-01-27 2017-11-30 Neuren Pharmaceuticals Limited Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline

Also Published As

Publication number Publication date
BR112015012506A2 (pt) 2017-07-11
JP2016506380A (ja) 2016-03-03
EP2928300A4 (fr) 2016-07-13
AU2013352294A1 (en) 2015-07-09
WO2014085480A1 (fr) 2014-06-05
EP2928300A1 (fr) 2015-10-14

Similar Documents

Publication Publication Date Title
CA2823218C (fr) Traitement de troubles du spectre autistique en utilisant l'acide glycyl-l-2-methylprolyl-l-glutamique
US11197856B2 (en) Bicyclic compounds and methods for their use in treating autism
US20150224164A1 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
WO2011147889A1 (fr) Procédés et composition pharmaceutiques pour le traitement d'un trouble de l'alimentation à début précoce chez un patient
EP2928300A1 (fr) Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique
US20190091284A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
US20180117113A1 (en) Amidated Dopamine Neuron Stimulating Peptide Restoration of Mitochondrial Activity
Ismailova et al. Lipopolysaccharide-induced depressive-like state and neuroinflammatory responses: differential effects on hippocampus and prefrontal cortex in wild-type mice

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20171128